ULTRAGENYX PHARMACEUTICAL INC. (RARE) Net income 2016–2025
ULTRAGENYX PHARMACEUTICAL INC. (RARE) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$575.0MFY2025 · since FY2016: -$245.9M → -$575.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$575.0M | -1.1% |
| FY2024 | -$569.0M | +6.3% |
| FY2023 | -$607.0M | +14.2% |
| FY2022 | -$707.4M | -55.8% |
| FY2021 | -$454.0M | -143.4% |
| FY2020 | -$186.6M | +53.7% |
| FY2019 | -$402.7M | -103.8% |
| FY2018 | -$197.6M | +34.6% |
| FY2017 | -$302.1M | -22.9% |
| FY2016 | -$245.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More RARE financial trends
RARE RevenueRARE Net marginRARE Gross profitRARE Gross marginRARE Operating incomeRARE Operating marginRARE Operating cash flowRARE Free cash flowRARE Capital expendituresRARE Return on equityRARE Stock buybacksRARE Dividends paidRARE Total assetsRARE Total liabilitiesRARE Shareholders’ equityRARE overview →